Advertisement
Journal Home
Search for

Volume 83, Issue 1, Pages 66-72 (January 2009)


View previous. 7 of 11 View next.

Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons

Yi LiuaCorresponding Author Informationemail address, George J. Yohrlingb, Yan Wanga, Tasha L. Hutchinsona, Douglas E. Brennemanb, Christopher M. Floresa, Boyu Zhaob

Received 28 April 2008; received in revised form 18 September 2008; accepted 23 September 2008.

Summary 

Carisbamate (RWJ-333369; (S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol) is a novel investigational antiepileptic drug that exhibits a broad-spectrum of activity in a number of animal models of seizure and drug refractory epilepsy. In an effort to understand the molecular mechanism by which carisbamate produces its antiepileptic actions, we studied its effects on the function of voltage-gated, rat brain sodium and potassium channels and on the repetitive firing of action potentials in cultured rat hippocampal neurons. In whole-cell patch clamp recording, carisbamate resulted in a concentration-, voltage- and use-dependent inhibition of rat Nav1.2, with an IC50 value of 68μM at −67mV. In rat hippocampal neurons, carisbamate similarly blocked voltage-gated sodium channels, with an IC50 value of 89μM at −67mV, and inhibited repetitive firing of action potentials in a concentration-dependent manner (by 46% at 30μM and 87% at 100μM, respectively). Carisbamate had no effect on the steady-state membrane potential or voltage-gated potassium channels (Kv) in these neurons. These inhibitory effects of carisbamate occurred at therapeutically relevant concentrations in vivo, raising the possibility that block of voltage-gated sodium channels by carisbamate contributes to its antiepileptic activity.

a Analgesics Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh & McKean Roads, P.O. Box 776, Spring House, PA 19477-0776, United States

b CNS Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh & McKean Roads, P.O. Box 776, Spring House, PA 19477-0776, United States

Corresponding Author InformationCorresponding author. Tel.: +1 215 628 5427; fax: +1 215 628 3297.

PII: S0920-1211(08)00277-5

doi:10.1016/j.eplepsyres.2008.09.006


View previous. 7 of 11 View next.

Advertisement